Anzeige
Mehr »
Dienstag, 01.07.2025 - Börsentäglich über 12.000 News
Nächster Kursturbo?: 226 % Plus seit Januar - wie weit kann diese Aktie noch steigen?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1CYFF | ISIN: CA03938C1041 | Ticker-Symbol:
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ARCH BIOPARTNERS INC Chart 1 Jahr
5-Tage-Chart
ARCH BIOPARTNERS INC 5-Tage-Chart

Aktuelle News zur ARCH BIOPARTNERS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.04.Arch Biopartners Inc: Arch partner TGH receives approval for phase II trial1
ARCH BIOPARTNERS Aktie jetzt für 0€ handeln
22.04.Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)1
11.04.Arch Biopartners Inc: Arch Biopartners 235,000-share private placement2
14.03.Arch Biopartners Inc: Arch Biopartners closes $374,000 private placement1
14.03.Arch Biopartners Closes Non-Brokered Private Placement1
05.03.Arch Biopartners Inc: Arch Biopartners arranges $350,000 private placement1
05.03.Arch Biopartners Arranges Non-Brokered Private Placement1
26.02.Arch Biopartners Inc: Arch Biopartners 31,112 shares for debt1
18.02.Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI)106TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the clinical team leading the upcoming investigator-led...
► Artikel lesen
04.02.Arch Biopartners Inc: Arch Biopartners arranges $57,246 shares for debt deal1
03.02.Arch Biopartners: Shares for Interest Debt Settlement1
08.01.Arch Biopartners Inc: Arch receives OK to proceed with phase II LSALT trial1
08.01.Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)122TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network Research Ethics...
► Artikel lesen
11.11.24Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury148TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun in...
► Artikel lesen
02.08.24Arch Biopartners' Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins144Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its unique...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1